Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

Experimental drug shows promise against NRAS-driven melanoma

A research team from Huntsman Cancer Institute at the University of Utah (the U) reports that a groundbreaking pathway-targeted therapy could be an effective treatment for certain melanoma patients and fill an unmet clinical need for patients with advanced disease.

16 Jul 2026

Blood-based gene tests show promise for pancreatic cancer screening

Researchers at Kanazawa University report the blood-based gene expression tests may enable early pancreatic cancer screening and improve long-term survival.

16 Jul 2026

New biological feedback loop helps the immune system attack colorectal cancers

A subset of cancers, known as microsatellite instability (MSI) and deficient DNA mismatch repair (dMMR) cancers, are more visible to the immune system than others.

16 Jul 2026

Experimental KRAS vaccine safely generates durable immune response against pancreatic cancer

Researchers at the Johns Hopkins Kimmel Cancer Center and its Skip Viragh Center for Pancreatic Cancer report that an experimental vaccine targeting mutant KRAS, one of the most common genetic drivers of pancreatic cancer, was safe and generated durable immune responses aimed at preventing the cancer in people at high risk.

16 Jul 2026

Researchers uncover new T cell attack mechanism against acute myeloid leukemia

Researchers at The University of Texas MD Anderson Cancer Center have discovered a new way in which T cells attack acute myeloid leukemia (AML) cells, which may help explain why AML is particularly sensitive to immune-based treatments and could guide the development of future cancer immunotherapies.

15 Jul 2026

AI model predicts effective immunotherapy combinations for liver cancer

Using computational tools, researchers from the Johns Hopkins Kimmel Cancer Center and the Johns Hopkins University School of Medicine have developed a method to predict which patients with a primary liver cancer called hepatocellular carcinoma (HCC) would most benefit from combination treatment using immunotherapy and a targeted therapy that blocks the growth signals that the tumor depends on.

15 Jul 2026

Unlocking the potential of organoids in modern drug discovery

Explore how organoids are unlocking new possibilities in modern drug discovery by improving disease modelling within DMTA-driven research workflows.

From TTP plc 15 Jul 2026

More than 50 million Americans lack local radiation cancer treatment

The disappearance of radiation oncology clinics threatens cancer care access for over 50 million Americans, with rural areas facing the greatest impact.

15 Jul 2026

Insilico and Bora Pharmaceuticals forge strategic AI-driven drug discovery alliance

Insilico Medicine, a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced a multi-target strategic alliance with Bora Pharmaceuticals Co., Ltd., a global leader in pharmaceutical manufacturing.

14 Jul 2026

New review highlights astrocytes' role in chronic traumatic encephalopathy

Researchers from Kansas City University School of Medicine have published a scoping review examining the role of astrocytes in chronic traumatic encephalopathy (CTE).

14 Jul 2026

Bifidobacterium-based oral vaccine enhances anti-tumor immunity in clinical study

A novel oral vaccine platform using genetically engineered Bifidobacterium could enhance anti-tumor immunity.

14 Jul 2026

Study reports a counterintuitive new approach to treating mesothelioma

Mesothelioma is a rare but aggressive cancer, usually caused by exposure to asbestos. Inhaled asbestos fibers become lodged in the lungs, causing inflammation that can lead to tumor formation decades later. Worldwide, about 30,000 people are diagnosed with mesothelioma each year.

14 Jul 2026

New consensus provides updated guidance for managing prolactinoma tumors

Prolactinomas are the most common functional pituitary neuroendocrine tumors, accounting for nearly half of all hormone-secreting pituitary adenomas.

13 Jul 2026

Weekly electronic symptom check-ins improve advanced cancer care

New results from an Alliance Foundation Trials (AFT) study reveal that a simple weekly electronic symptom check-in with care team, significantly improves the quality of life for individuals undergoing treatment for advanced cancer.

13 Jul 2026

Robot-guided surgery successfully drains multiple deep brain abscesses

Brain abscesses located deep within the brain can rapidly become life-threatening and are often difficult to treat through conventional surgery. Brain abscesses located deep within the brain can rapidly become life-threatening and are often difficult to treat through conventional surgery.

13 Jul 2026

Insurance-supported integrative oncology symptom management program benefits cancer patients

A new study from University Hospitals Connor Whole Health reports that an insurance-supported integrative oncology program resulted in clinically meaningful improvements in cancer-related symptoms like pain, stress, anxiety, depression, nausea, and fatigue.

11 Jul 2026

Harvard University hosts the world's largest conference dedicated to longevity biotechnology

The 13th Aging Research & Drug Discovery (ARDD) Meeting, the world's largest conference dedicated to longevity biotechnology, will take place from October 1-3, 2026, at the David Rubenstein Treehouse at Harvard University.

11 Jul 2026

Rural radiation oncology clinic closures threaten cancer patient care

A new study led by researchers at the Icahn School of Medicine at Mount Sinai found that although the overall number of radiation oncology clinics in the United States has appeared stable in recent years, many individual treatment centers have quietly closed while others have opened.

11 Jul 2026

Machine learning redefines precision cancer therapy using smart radiopharmaceuticals

JMIR Publications released a feature News and Perspectives story on technological advances in oncology.

11 Jul 2026

New generation approaches revive BET protein inhibitors in solid tumors

BET proteins, especially BRD4, drive oncogenic transcription in solid tumours. First‑generation inhibitors (JQ1, molibresib, birabresib) showed preclinical promise but failed clinically due to modest efficacy, dose‑limiting thrombocytopenia, and resistance (isoform switching, compensatory PI3K/AKT/WNT signalling).

11 Jul 2026